Insiders · KDNY

Eric Dobmeier

Officer, Director at Chinook Therapeutics, Inc. (KDNY)

Eric Dobmeier has filed 31 insider reports with the SEC since February 2021, as director at Structure Therapeutics Inc. (GPCR), director at Janux Therapeutics, Inc. (JANX) and director at Jade Biosciences, Inc. (JBIO) and at 3 more companies. Eric Dobmeier made no open-market purchases or sales in the last 12 months. The latest filing, on June 18, 2026, reports grant or award at Structure Therapeutics Inc. (GPCR).

Filings
31
Companies
6
Bought on market
$323K
Sold on market
$2.18M

Companies where Eric Dobmeier is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Structure Therapeutics Inc. logo
GPCR
Structure Therapeutics Inc.
Director$17.12Jun 18, 2026
Janux Therapeutics, Inc. logo
JANX
Janux Therapeutics, Inc.
Directorsince July 202415,481$10.29Jun 13, 2026
Jade Biosciences, Inc. logo
JBIO
Jade Biosciences, Inc.
Directorsince April 2025$15.06May 1, 2025
Atara Biotherapeutics, Inc. logo
ATRA
Atara Biotherapeutics, Inc.
Director563,325$101K$0.23$6.34+2657%Nov 14, 2023
Chinook Therapeutics, Inc. logo
KDNY
Chinook Therapeutics, Inc.
Officer, Director0$222K$2.18M$12.32Aug 11, 2023
Adaptive Biotechnologies Corp logo
ADPT
Adaptive Biotechnologies Corp
Director1,504$28.05Feb 18, 2021

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.

Every filing

Also sits on boards with

Officers and directors who share two or more companies with Eric Dobmeier.

Compare Eric Dobmeier with

Other insiders at the same companies

Questions about Eric Dobmeier

What is Eric Dobmeier's role at Chinook Therapeutics, Inc.?
Eric Dobmeier reports to the SEC as officer and director at Chinook Therapeutics, Inc. (KDNY), according to the latest filing on August 11, 2023. Eric Dobmeier has also filed as director at Structure Therapeutics Inc. (GPCR), director at Janux Therapeutics, Inc. (JANX), director at Jade Biosciences, Inc. (JBIO) and director at Atara Biotherapeutics, Inc. (ATRA).
How many shares does Eric Dobmeier own?
After the latest filing that states it, Eric Dobmeier directly owned 15,481 shares of Janux Therapeutics, Inc. (JANX), 563,325 shares of Atara Biotherapeutics, Inc. (ATRA) and 1,504 shares of Adaptive Biotechnologies Corp (ADPT). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Eric Dobmeier bought or sold stock recently?
The most recent open-market purchase was on November 10, 2023: bought 446,825 shares of Atara Biotherapeutics, Inc. (ATRA) for $101K at an average of $0.23. The most recent open-market sale was on April 24, 2023: sold 23,800 shares of Chinook Therapeutics, Inc. (KDNY) for $514K at an average of $21.58.
How do I get alerts when Eric Dobmeier files?
Follow Eric Dobmeier on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Eric Dobmeier (SEC CIK 0001202785). Totals count each trade once, skipping amendments whose original is on file, from Feb 12, 2021 on. View on SEC EDGAR · Get this as JSON